Hussein Tawbi, MD, PhD, discusses recent study updates and advances in the treatment of melanoma through the context of two patient cases.
EP. 1: Case Presentation: A 78-Year-Old Man With Metastatic Melanoma
Hussein Tawbi, MD, PhD, presents the case of a 78-year-old man with metastatic melanoma and shares his initial impressions.
EP. 2: Common Clinical Presentations of Metastatic Melanoma
Hussein Tawbi, MD, PhD, details the incidence rate of melanoma and that appropriate diagnosis includes an MRI to check for brain metastases and molecular testing for BRAF mutations.
EP. 3: Significance of Biomarker and Genetic Testing in Diagnosing Metastatic Melanoma
Hussein Tawbi, MD, PhD, highlights the importance of BRAF mutations and LDH levels in diagnosing patients with metastatic melanoma and guiding treatment.
EP. 4: Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma
Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.
EP. 5: The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma
Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.
EP. 6: Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial
The RELATIVITY-047 trial evaluated relatlimab and nivolumab versus nivolumab alone in patients with metastatic melanoma, revealing improved progression-free survival, while PDL-1 status wasn't predictive of outcomes.
EP. 7: IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma
Hussein Tawbi, MD, PhD, emphasizes that combination immunotherapies offer higher efficacy than single agent PD-1 inhibitors for metastatic melanoma; however, patient characteristics guide the choice of treatment regimen, with toxicities playing a key role.
EP. 8: Key Trial Data in the Frontline Treatment of Metastatic Melanoma
Over the past decade, the frontline treatment landscape for metastatic melanoma has evolved with studies like CheckMate-067 and KEYNOTE-006 highlighting the superiority of PD-1-based therapies over ipilimumab, and recent trials introducing new combination treatments.
EP. 9: Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy
Hussein Tawbi, MD, PhD, emphasizes the importance of patient education in managing adverse events from the treatment of metastatic melanoma with checkpoint inhibition, discussing symptom recognition, potential side effects, and treatment adjustments while ensuring team accessibility and patient communication.
EP. 10: Case Presentation: A 67-Year-Old Woman With Stage IV Melanoma
Hussein Tawbi, MD, PhD, presents the case of a 67-year-old woman with stage IV melanoma and shared his initial impressions.
EP. 11: Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation
Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.
EP. 12: Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial
The phase 3 DREAMseq trial compared initial treatments of combination immunotherapy or BRAF/MEK inhibitors for B-Raf mutated melanoma, showing a 20% overall survival benefit at 2 years for immunotherapy as the first-line treatment.
EP. 13: Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression
Hussein Tawbi, MD, PhD, explains that if a patient with metastatic melanoma and a BRAF mutation progresses after initial checkpoint inhibitors, either combination immunotherapy or MEK inhibitor therapy is considered, based on disease progression pace and pattern.
EP. 14: Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma
Hussein Tawbi, MD, PhD, closes his discussion by sharing some clinical pearls for fellow oncologists treating patients with metastatic melanoma.
2 Clarke Drive Cranbury, NJ 08512